Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org
Dallas, Texas (PRWEB) July 30, 2014 -- “PharmaSphere: Emerging Biotech Investment Report Strategic Trends in Private Equity and Venture Capital Funding” report provides in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry, bearing in mind that these are expected to have significant impact on the future of emerging biotechnology companies in the US and globally. Furthermore, the report identifies regions of the world that are attracting more investments in healthcare and discusses the various factors responsible for this trend. In addition, the report provides detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013.
Order a Purchase copy @ http://www.marketoptimizer.org/contacts/purchase?rname=5634 .
Private Equity Firms: Company Drill-Downs:
• TPG Capital
• The Carlyle Group
• The Blackstone Group
• Kohlberg Kravis Roberts
• Warburg Pincus
• Goldman Sachs Principal Investment Area
• Advent International Corporation
• Apollo Global Management
• Bain Capital
• CVC Capital Partners
• Oaktree Capital Management
• Hellman & Friedman
Venture Capital Firms: Company Drill-Downs:
• New Enterprise Associates
• OrbiMed Advisor
• Canaan Partners
• Versant Ventures
• New Leaf Venture Partners
• Third Rock Ventures
• Domain Associates
• Kleiner Perkins Caufield & Byers
• Clarus Ventures
• Flagship Ventures
Key Questions Answered
• What are the current trends impacting emerging biotechnology investment in the US and globally?
• What regions are witnessing noteworthy investment in healthcare and what are the factors driving such occurrences?
• What therapeutic areas are attracting the most investment by private equity and venture capital firms and why?
• What has been the trend of equity offerings in the healthcare sector since 2004 and what factors were responsible?
• What is the strategic outlook of emerging biotechnology investment?
Complete Report Details @ http://www.marketoptimizer.org/pharmasphere-emerging-biotech-investment-report-strategic-trends-in-private-equity-and-venture-capital-funding.html .
This report is an essential source of information and analysis on emerging biotech investment, with significant emphasis on the US. GlobalData provides an in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry. The report highlights the various therapeutic areas attracting noteworthy funding in terms of the volume and value of new and follow-on investments and discusses the factors responsible for this trend. Furthermore, it provides a strategic outlook on future trends that are expected in private equity and venture capital funding and how they will impact the growth and development of biotech companies globally.
Major Points from Table of Content:
3 US Private Equity and Venture Capital Industry Dynamics 21
3.1 Post-2008 Financial Market Crash: Volume of Capital Commitments to Private Equity Funds Show Signs of Recovery 21
3.2 Volume over Value: Decrease in the Average Value of Completed Private Equity Healthcare Deals between 2007 and 2013 24
3.3 Healthcare Reform and Cost Pressures in Europe and North America Shifts Deal Activity to the Asia-Pacific Region 25
3.4 Private Equity Deals by Therapy Area 28
3.5 Private Equity Buyouts of 2013 30
3.6 Venture Capital Investment Trend 31
3.7 Venture Capital Investment: Biotechnology Plays Second Fiddle to Software 34
3.8 Seed-Stage Financing Shows Downward Trend 37
3.9 Venture-Backed Exits in 2013 38
3.10 California, Massachusetts, and New York Lead the Pack in Venture Capital Investment for 2013 42
4 Equity Offerings 44
4.1 Equity Offerings in the Healthcare Sector 44
4.2 Venture-Backed Initial Public Offerings in 2013 45
4.3 Venture-Backed Emerging Biotech Initial Public Offerings in 2013 46
4.4 Liquidity Position Makes Emerging Biotechs an Attractive Prospect for Investors 47
4.5 Company Profiles and Initial Public Offer Details 49
4.5.1 Intrexon Corporation (Stock Symbol: XON) 49
4.5.2 Ophthotech Corporation (Stock Symbol: OPHT) 51
4.5.3 PTC Therapeutics (Stock Symbol: PTCT) 52
4.5.4 Portola Pharmaceuticals (Stock Symbol: PTLA) 54
4.5.5 Agios Pharmaceuticals (Stock Symbol: AGIO) 55
4.5.6 Chimerix (Stock Symbol: CMRX) 57
4.5.7 Bluebird Bio (Stock Symbol: BLUE) 58
4.5.8 Foundation Medicine (Stock Symbol: FMI) 59
4.5.9 OncoMed Pharmaceuticals (Stock Symbol: OMED) 60
4.5.10 Acceleron Pharma (Stock Symbol: XLRN) 62
4.5.11 Prosensa Therapeutics (Stock Symbol: RNA) 64
4.5.12 Epizyme (Stock Symbol: EPZM) 65
4.5.13 Onconova Therapeutics (Stock Symbol: ONTX) 66
4.5.14 Tetraphase Pharmaceuticals (Stock Symbol: TTPH) 68
4.5.15 Esperion Therapeutics (Stock Symbol: ESPR) 69
Explore more reports on Biotechnology industry at http://www.marketoptimizer.org/category/life-sciences/biotechnology .
About Us:
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, Market Optimizer, http://www.marketoptimizer.org/, +1 (888) 391-5441, [email protected]
Share this article